These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19043778)

  • 61. Bevacizumab plus irinotecan in recurrent glioblastoma.
    Chamberlain MC
    J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
    [No Abstract]   [Full Text] [Related]  

  • 62. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Chamberlain MC
    Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
    [No Abstract]   [Full Text] [Related]  

  • 64. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
    Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
    Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA
    J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
    Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
    Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
    Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
    Fraum TJ; Kreisl TN; Sul J; Fine HA; Iwamoto FM
    J Neurooncol; 2011 Nov; 105(2):281-9. PubMed ID: 21603965
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
    Farina P; Tabouret E; Lehmann P; Barrie M; Petrirena G; Campello C; Boucard C; Graillon T; Girard N; Chinot O
    J Neurooncol; 2017 May; 132(3):433-437. PubMed ID: 28265824
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.
    Rajan B; Ross G; Lim CC; Ashley S; Goode D; Traish D; Brada M
    Eur J Cancer; 1994; 30A(12):1809-15. PubMed ID: 7880611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antiangiogenic therapy in malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Curr Opin Oncol; 2008 Nov; 20(6):652-61. PubMed ID: 18841047
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
    Torcuator R; Zuniga R; Loutfi R; Mikkelsen T
    J Neurooncol; 2009 Jul; 93(3):409-12. PubMed ID: 19139822
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
    Batchelor TT; Gilbert MR; Supko JG; Carson KA; Nabors LB; Grossman SA; Lesser GJ; Mikkelsen T; Phuphanich S;
    Neuro Oncol; 2004 Jan; 6(1):21-7. PubMed ID: 14769136
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The emerging role of anti-angiogenic therapy for malignant glioma.
    Reardon DA; Desjardins A; Rich JN; Vredenburgh JJ
    Curr Treat Options Oncol; 2008 Feb; 9(1):1-22. PubMed ID: 18256938
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
    Lamborn KR; Yung WK; Chang SM; Wen PY; Cloughesy TF; DeAngelis LM; Robins HI; Lieberman FS; Fine HA; Fink KL; Junck L; Abrey L; Gilbert MR; Mehta M; Kuhn JG; Aldape KD; Hibberts J; Peterson PM; Prados MD;
    Neuro Oncol; 2008 Apr; 10(2):162-70. PubMed ID: 18356283
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.
    Tuettenberg J; Grobholz R; Seiz M; Brockmann MA; Lohr F; Wenz F; Vajkoczy P
    J Cancer Res Clin Oncol; 2009 Sep; 135(9):1239-44. PubMed ID: 19277712
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model.
    Jahnke K; Muldoon LL; Varallyay CG; Lewin SJ; Kraemer DF; Neuwelt EA
    Neuro Oncol; 2009 Apr; 11(2):142-50. PubMed ID: 18772353
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
    Yan C; Wang J; Yang Y; Ma W; Chen X
    J Cell Mol Med; 2019 Aug; 23(8):4876-4882. PubMed ID: 31210419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.